

# EGIDE

Euronext Growth - FR0000072373 – ALGID

## ✓ EGIDE Gains Time

- ✓ Capital increase of €1.67M
- ✓ Subscription rate 92.5%
- ✓ Issue price €0.5

Initially, Egide aimed to raise €1.8M, with 83% guaranteed by iXCore Group (€1.45M) and Sogefip, a company affiliated with Michel Faure, for €50K.

Note that 3.3 million warrants (BSA) will be detached on November 13, admitted for trading, and exercisable until May 13, 2026. Two warrants will entitle the holder to subscribe to one share at a price of €0.65. If all warrants were exercised, this would lead to an additional capital increase of €1M.

Assuming that iXCore and Sogefip were allocated 100% of their requested shares, additional demand amounted to €171K. Excluding "guarantors," this is low compared to previous transactions last year (oversubscribed 2.2 times in September 2023 and 1.5 times in December). We believe the lower interest is due to the significant premium applied. Since the issue price could not be set below the nominal value of €0.5 per share, the premium was 56.6% compared to the average share price over the 20 trading days prior to setting the issue price, and 68.9% compared to the price before the announcement.

For comparison, in the capital increase in September 2023, the discount was 14.3% relative to the last 20 trading sessions and 26.4% relative to the last session. That transaction was fully guaranteed but without restrictions.

As for the capital increase in December, it carried a slight premium of 7% and 4.8%, respectively, but subscription commitments were made on an irreducible and, if necessary, reducible basis. It was during this time that iXCore joined the capital at a price of €0.65.

### Outlook

As we mentioned, this cash injection will give the group some breathing room, but it may not be sufficient to support the restructuring, particularly for Egide USA, which remains a challenging issue for management. Cambridge is facing major industrial difficulties, which are very costly for the group.

Currently, we forecast for Egide USA a decrease in activity in 2024 of -18% to €9.6M (\$10.4M) and an EBIT of -€1.6M vs. -€1.9M in 2023. In H1 2024, activity declined by -18.8%, and EBIT was -€0.8M. For 2025-2027, we expect annual growth of +10%, reaching a revenue of \$12.7M in 2026, a level achieved in 2019. Egide USA has exceeded \$12M in revenue three times in five years, making this target achievable.

In terms of EBIT, we are targeting -€1M in 2025, then -€0.4M, with a return to breakeven in 2027. These assumptions rely on a rapid and effective turnaround for Cambridge, with a significant reduction in waste, one of Egide USA's current weaknesses.

To reiterate, unless Cambridge's recovery happens quickly, we believe a larger operation will be needed in 2025 to secure Egide's development. iXCore's presence in the group's capital is crucial and largely determines its future.

**Opinion & Target Price:** Neutral / €0.50

**Arnaud Riverain**  
+ 33 (0)6 43 87 10 57  
ariverain@greensome-finance.com

# NEUTRAL

## Capital Increase Results

BPI Label – Innovative company- PEA-PME Eligible

**TARGET** BEFORE  
**€ 0.50** € 0.50

**SHARE PRICE** (11/11/24) POTENTIAL  
**€ 0.474** **+5.5%**

**CAPITALISATION** FLOTTANT  
**€ 9.29m** € 6.1m

Ratios	2024e	2025e	2026e
EV/Sales	0,63	0,58	0,53
EV/EBIT	nr	nr	28,6
P/E	nr	nr	nr
P/CF	-37,4	50,1	6,0
Dividend Yield	0,0	0,0	0,0

Data per share	2023	2024e	2025e	2026e
EPS	-0,19	-0,17	-0,10	-0,02
%Change	nr	nr	nr	nr
FCF	0,03	-0,04	-0,02	0,05
%Change	nr	nr	nr	nr
Dividend	-	-	-	-

Income Statement (€m)	2023	2024e	2025e	2026e
Net Sales	36,7	30,3	33,0	35,9
%Change	137,4%	-17,5%	8,9%	8,9%
EBIT	-2,1	-2,2	-0,8	0,7
% Sales	-5,6%	-7,1%	-2,3%	1,9%
Net Result	-3,1	-3,2	-1,9	-0,4
% Sales	-8,5%	-10,7%	-5,6%	-1,2%

Cash Flow Statement (€m)	2023	2024e	2025e	2026e
FCF	0,5	-0,7	-0,3	1,0
Net Debt	9,8	11,3	12,8	12,9
Shareholder Equity	7,0	5,5	3,6	3,2
Gearing	138,8%	207,9%	355,0%	406,1%
ROCE	-7,4%	-7,9%	-2,9%	2,5%

Shareholders	
iXcore	8,5%
Pleiade Venture	8,0%
Vatel Remploi	7,4%
Free Float	65,3%

Performances	2024	3m	6m	1 Year
Egide	-35,0%	10,5%	-26,6%	-24,8%
Euronext Growth	-9,8%	-3,2%	-7,3%	-4,9%
12 months Low-High	0,22	0,99		

Liquidity	2024	3m	6m	1 Year
Cumulative volume (000)	8 913	1 759	3 130	9 961
% of capital	45,5%	9,0%	16,0%	50,8%
% of Free Float	69,6%	13,7%	24,5%	77,8%
€ Million	5,6	0,6	1,3	6,3

**Next Event** 2024 Annual Sales : january, 20

*Egide has signed a research contract with GreenSome.*


## Snapshot Egide

Egide articulates its activity through two technologies that are glass-metal and ceramic cases which makes it one of the few actors in the world to control them. These housings make it possible to ensure perfect hermeticity in environments that may be subject to high thermal and / or atmospheric stresses. Egide provides highly resistant interconnection boxes in sensitive environments (Space, Defense, Security, Aeronautics, Telecommunications, Energy, ...), solutions that guarantee the optimal reliability of electronic systems or complex chips. In February 2017, the group acquired Santier, a US company specializing in the manufacture of dissipative components and materials.

## Fondamental Matrix



## Investment Profile



## Target Price & rating history

Date	Type	Opinion	Price per share	Price Target
10/21/24	H1 results	Neutral	€ 0.304	€ 0.5
7/16/24	Sales H1	Neutral	€ 0.497	€ 0.5
4/30/24	2023 Annual Results	Buy	€ 0.608	0.87 €
1/29/24	Sales 2023	Neutral	€ 0.972	€ 0.95
12/12/23	Capital Increase Result	Speculative Buy	€ 0.64	€ 1.16
11/21/23	Capital Increase	Speculative Buy	€ 0.591	€ 1.16
10/24/23	H1 Results	Speculative Buy	€ 0.54	€ 1.16

## Financial Data

Income Statement (€ m)	2021	2022	2023	2024e	2025e	2026e
Revenues	32,5	15,5	36,7	30,3	33,0	35,9
Purchase	12,7	5,7	14,9	10,6	11,2	11,9
Externals costs	6,5	2,4	5,1	4,8	4,9	5,2
Personnals Costs	14,0	6,3	16,3	14,6	15,1	15,7
Amortization	1,5	0,5	2,2	2,1	2,1	2,1
other	3,4	0,1	0,0	0,0	0,0	0,0
<b>EBIT</b>	<b>0,8</b>	<b>0,6</b>	<b>-2,1</b>	<b>-2,2</b>	<b>-0,8</b>	<b>0,7</b>
Financial Result	-0,4	-0,2	-1,1	-1,1	-1,1	-1,1
Tax	-0,2	-0,1	0,0	0,0	0,0	0,0
<b>Net Result</b>	<b>0,2</b>	<b>0,3</b>	<b>-3,1</b>	<b>-3,2</b>	<b>-1,9</b>	<b>-0,4</b>

Balance Sheet (€ m)	2021	2022	2023	2024e	2025e	2026e
Fixed Assets	12,8	2,5	9,5	9,5	8,3	7,2
Stock Inventories	7,4	3,5	7,0	6,3	6,9	7,5
Accounts Receivable	4,9	3,4	6,3	5,9	6,4	7,0
Other Currents Assets	1,6	1,9	2,1	2,1	2,3	2,5
Cash & Equivalents	1,6	0,7	3,2	0,5	-0,4	0,0
<b>TOTAL Assets</b>	<b>28,3</b>	<b>27,9</b>	<b>28,2</b>	<b>24,3</b>	<b>23,4</b>	<b>24,1</b>
Shareholders' Equity	11,6	6,5	7,0	5,5	3,6	3,2
Provisions	0,9	0,7	0,8	0,7	0,8	0,8
Financial Debt	7,7	4,6	9,2	8,4	8,9	9,4
Accounts Payables	5,4	2,7	6,5	5,5	6,0	6,5
<b>TOTAL Liabilities</b>	<b>28,3</b>	<b>27,9</b>	<b>28,2</b>	<b>24,3</b>	<b>23,4</b>	<b>24,1</b>

Cash Flow Statements (€ m)	2021	2022	2023	2024e	2025e	2026e
Cash Flow from Operating Activities	-1,2	0,9	-0,2	-0,4	1,0	2,4
Change in Net Working Capital	0,7	-1,4	1,1	-0,2	0,8	0,9
Cash Flow from Operations	-0,5	-0,5	0,8	-0,2	0,2	1,6
Cash Flow from Investing	0,1	-0,1	-0,3	-0,5	-0,5	-0,5
Capital Increase	0,0	0,0	3,7	1,7	0,0	0,0
Funding Flow	0,2	0,9	0,0	-1,8	0,1	0,1
Cash Flow from Financing	0,5	0,8	1,7	-2,0	-0,6	-0,6
<b>Net Change in cash position</b>	<b>0,2</b>	<b>-0,9</b>	<b>2,1</b>	<b>-2,7</b>	<b>-0,9</b>	<b>0,4</b>

RATIOS	2021	2022	2023	2024e	2025e	2026e
EBIT Margin	2,5%	3,8%	-5,6%	-7,1%	-2,3%	1,9%
Net Margin	0,6%	2,2%	-8,5%	-10,7%	-5,6%	-1,2%
ROE	1,7%	5,2%	-44,4%	-59,5%	-51,8%	-13,4%
ROCE	2,6%	4,6%	-7,4%	-7,9%	-2,9%	2,5%
Gearing	72,0%	75,8%	138,8%	207,9%	355,0%	406,1%

Estimates : GreenSome Finance

## Rating Definition

BUY	NEUTRAL	SELL
Upside > +10%	-10% < Upside < +10%	Upside < -10%

## Disclosures

Corporate Finance operation in progress or completed during the last 12 months	GreenSome Consulting and affiliate owns common equity securities of this subject company	Financial Analysis Contract	Notice to the company before publication	Liquidity Contract	Liquidity Provider
NO	NO	YES	YES	NO	NO

This publication was prepared by Greensome Finance on behalf of GreenSome Consulting. It is issued for informational purposes only and does not constitute a solicitation of orders to buy or sell securities mentioned therein.

The information contained in this publication and all opinions contained therein are based on sources believed reliable. However Greensome Consulting does not warrant the accuracy or completeness of this information and no one can rely. All opinions, projections and / or estimates contained in this publication reflect the decision of Greensome Consulting on the date and may be subject to change without notice. This publication is for informational purposes only to professional investors who are supposed to develop their own investment decisions without relying improperly on this publication. Investors must make their own judgments about the appropriateness of investing in any securities mentioned in this publication taking into account the merits and risks attached to them, their own investment strategy and their legal status, fiscal and financial. Past performance is by no means a guarantee for the future. Because of this publication, neither Greensome Consulting nor any of its officers or employees, cannot be held responsible for any investment decision. In accordance with the regulations and to prevent and avoid conflicts of interest with respect to any investment recommendations, Greensome Consulting has developed and maintains an effective operational management of conflicts of interest. The system for managing conflicts of interest is to prevent, with reasonable certainty, any breach of the principles and rules of professional conduct. It is constantly updated to reflect regulatory changes and changes in the activity of Greensome Consulting. Greensome Consulting intends at all times, act with respect for the integrity of the market and the primacy of the interests of its customers. To this end, Greensome Consulting has set up an organization's business and the procedures commonly called "Chinese Wall" whose purpose is to prevent the improper circulation of confidential information, and organizational and administrative arrangements to ensure transparency in situations likely to be perceived as conflicts of interest by investors. This publication is in terms of its distribution in the UK, only for people considered persons licensed or exempt under the Financial Services Act 1986 in the United Kingdom or any regulations passed under it or to persons as described in section 11 (3) of the Financial Services Act 1986 (Investment Advertisement) (Exemptions) Order 1997 and is not intended to be distributed or communicated, directly or indirectly, to any other type of person. The distribution of this publication in other jurisdictions may be restricted by applicable law, and anyone who would come to be in possession of this book should learn and observe such restrictions.